Comparing the current results to its competitors, Neurocrine Biosciences Inc reported Revenue increase in the 2 quarter 2026 by 39.49 % year on year. The sales growth was above Neurocrine Biosciences Inc 's competitors' average revenue growth of 32.15 %, achieved in the same quarter.
Neurocrine Biosciences Inc 's Comment on Competition and Industry Peers
The United States, the European Union, and Japan grant data and marketing exclusivity for new medicinal compounds, restricting competitors from using the original applicant's data for generic marketing applications during the exclusivity period. This period typically lasts five years in the United States, six years in Japan, and eight years in the European Union, with additional marketing exclusivity available in the EU. For biologics, the United States provides 12 years of exclusivity under the Biologics Price Competition and Innovation Act.
Strong sales growth of 39.49 % in Overall company contributed to Neurocrine Biosciences Inc increase in total revenue by 39.49 % Neurocrine Biosciences Inc improved its market share in this segment, to approximately 64.09 %.
Publicly Traded Peers of Neurocrine Biosciences Inc
Acadia Pharmaceuticals Inc Share Performance
-5.24%
30 Days
Acadia Pharmaceuticals Inc
Profile
Acadia Pharmaceuticals Inc's business model centers around the research, development, and commercialization of innovative medicines for diseases related to the central nervous system. They collaborate with a network of partners and employ a combination of in-house research and licensing agreements to discover and develop drug candidates. Their primary revenue stream comes from the sales of approved products, with a focus on providing effective therapeutic options for patients with unmet medical needs.
Minerva Neurosciences Inc is a biopharmaceutical company that primarily focuses on the development and commercialization of innovative therapies for central nervous system disorders. They aim to identify potential drug candidates, conduct clinical trials, and collaborate with partners to bring novel treatments to market.
Nexalin Technology Inc is a company that operates on a business model centered around providing innovative neuromodulation therapies. Their approach involves utilizing proprietary technology to offer non-invasive treatment options for mental health disorders such as depression, anxiety, and addiction. By delivering safe and effective solutions, Nexalin aims to improve the quality of life for their patients, revolutionizing the field of neuromodulation.
Ovid Therapeutics Inc's business model is focused on developing and commercializing innovative medicines for the treatment of rare neurological disorders.
Sources:
Neurocrine Biosciences Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Neurocrine Biosciences Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
